Related references
Note: Only part of the references are listed.Development of Sanofi Pasteur tetravalent dengue vaccine
Bruno Guy et al.
HUMAN VACCINES (2010)
A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults
Dennis Morrison et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults
Wellington Sun et al.
HUMAN VACCINES (2009)
Recent progress on sanofi pasteur's dengue vaccine candidate
Jean Lang
JOURNAL OF CLINICAL VIROLOGY (2009)
Changing Patterns of Dengue Epidemiology and Implications for Clinical Management and Vaccines
Cameron P. Simmons et al.
PLOS MEDICINE (2009)
Spatial Evaluation and Modeling of Dengue Seroprevalence and Vector Density in Rio de Janeiro, Brazil
Nildimar Alves Honorio et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
Global Spread and Persistence of Dengue
Jennifer L. Kyle et al.
ANNUAL REVIEW OF MICROBIOLOGY (2008)
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4
Joseph E. Blaney et al.
VACCINE (2008)
Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages
Mammen P. Mammen et al.
PLOS MEDICINE (2008)
Antibody to dengue 1 detected more than 6 years after infection
Allison Imrie et al.
VIRAL IMMUNOLOGY (2007)
Prospects for a dengue virus vaccine
Stephen S. Whitehead et al.
NATURE REVIEWS MICROBIOLOGY (2007)
Prevalence of neutropenia in the US population: Age, sex, smoking status, and ethnic differences
Matthew M. Hsieh et al.
ANNALS OF INTERNAL MEDICINE (2007)
The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers
Anna P. Durbin et al.
HUMAN VACCINES (2006)
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity
Farshad Guirakhoo et al.
HUMAN VACCINES (2006)
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults
S Kitchener et al.
VACCINE (2006)
Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
JE Blaney et al.
JOURNAL OF VIROLOGY (2005)
rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
AP Durbin et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates
F Guirakhoo et al.
JOURNAL OF VIROLOGY (2004)
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children
A Sabchareon et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3 ' untranslated region is highly attenuated and immunogenic in monkeys
SS Whitehead et al.
JOURNAL OF VIROLOGY (2003)
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
N Kanesa-thasan et al.
VACCINE (2001)
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
DW Vaughn et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
